Compound E, chemically designated as 209986-17-4 (CAS), represents a significant exploration within the field of Alzheimer's illness research. This γ-secretase inhibitor was initially developed as a potential therapeutic approach aimed at reducing the generation of amyloid-beta peptides, which are believed to be central contributors to the formati